Everything below concerns synaptogenesis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Ajinomoto Co., Inc. (味の素株式会社, Ajinomoto kabushiki gaisha; Japanese pronunciation: [a.(d)ʑi.noꜜ.mo.to]) is a Japanese multinational food and biotechnology corporation which produces seasonings, cooking oils, frozen foods, beverages, sweeteners, amino acids, insulating films, and pharmaceuticals. Aji-No-Moto (味の素, "essence of taste") is the trade name for the company's original monosodium glutamate (MSG) product, the first of its kind, since 1909. The corporation's head office is located in Chūō, Tokyo. As of 2024, Ajinomoto operates in 31 countries worldwide and employs an estimated 34,862 people. Its yearly revenue in 2024 is around ¥1.53 trillion JPY or $10.61 billion USD.
In gas chromatography, the Kovats retention index (shorter Kovats index, retention index; plural retention indices) is used to convert retention times into system-independent constants. The index is named after the Hungarian-born Swiss chemist Ervin Kováts (1927–2012), who outlined the concept in the 1950s while performing research into the composition of the essential oils. The retention index of a chemical compound is retention time interpolated between adjacent n-alkanes. While retention times vary with the individual chromatographic system (e.g. with regard to column length, film thickness, diameter and inlet pressure), the derived retention indices are quite independent of these parameters and allow comparing values measured by different analytical laboratories under varying conditions and analysis times from seconds to hours. Tables of retention indices are used to identify peaks by comparing measured retention indices with the tabulated values.
A bone growth factor is a growth factor that stimulates the growth of bone tissue. Known bone growth factors include insulin-like growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2), transforming growth factor beta (TGF-β), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), parathyroid hormone-related peptide (PTHrP), bone morphogenetic proteins (BMPs), and certain members of the growth differentiation factor (GDF) group of proteins. The ultimate target of bone growth factors are osteoblasts, osteoclasts and fibroblasts. Human fibroblasts and osteoblasts were shown to be capable of producing bone growth factors after stimulation. Major hormones influencing bone growth and morphology include growth hormone (GH), androgens such as testosterone and dihydrotestosterone, and estrogens such as estradiol.
One of the main factors driving the Mexican drug war is widespread poverty. From 2004 to 2008, the portion of the population who received less than half of the median income rose from 17% to 21%, and the proportion of the population living in extreme or moderate poverty rose from 35% to 46% (52 million persons) between 2006 and 2010. Among the OECD countries, Mexico has the second-highest economic disparity between the extremely poor and the rich. The bottom ten percent in the income hierarchy has 1.36% of the country's resources, whereas the upper ten percent has almost 36%. The OECD also notes that Mexico's budgeted poverty alleviation and social development expenses are only about a third of the OECD average. In 2012, it was estimated that Mexican cartels employed over 450,000 people directly, and a further 3.2 million people's livelihoods depended on various parts of the drug trade. In cities such as Ciudad Juárez, up to 60% of the economy depended on illegal sources of income. As of 2023, an estimated 175,000 people are working for the cartels. The head of the U.S. Drug Enforcement Administration (DEA) reported that there are an estimated 45,000 members, associates, and brokers spread over more than 100 countries working under the Sinaloa cartel and the Jalisco New Generation cartel.
Sources: en.wikipedia.org
These effects were not noted in its medicinal use in the 1950s and 1960s, and reports of physical violence on PCP have often been shown to be unfounded. Recreational doses of the drug also occasionally appear to induce a psychotic state, with emotional and cognitive impairment that resembles a schizophrenic episode. Users generally report feeling detached from reality. Symptoms are summarized by the mnemonic device RED DANES: rage, erythema (redness of skin), dilated pupils, delusions, amnesia, nystagmus (oscillation of the eyeball when moving laterally), excitation, and skin dryness.
Brazilian cuisine varies greatly by region, reflecting the country's varying mix of indigenous and immigrant populations. This has created a national cuisine marked by the preservation of regional differences. Some of the most well known Brazilian foods are the feijoada, considered the country's national dish; and churrasco, a kind of barbecue which is often served in rodízio style. Other regional foods include beijú, feijão tropeiro, vatapá, moqueca, polenta (from Italian cuisine) and acarajé (from African cuisine). The national beverage is coffee; cachaça is Brazil's native liquor. Cachaça is distilled from sugar cane and is the main ingredient in the national cocktail, Caipirinha. A typical meal consists mostly of rice and beans with beef, salad, french fries and a fried egg. Often, it is mixed with cassava flour (farofa). Fried potatoes, fried cassava, fried banana, fried meat and fried cheese are very often eaten in lunch and served in most typical restaurants. Popular snacks are pastel (a fried pastry); coxinha (a variation of chicken croquete); pão de queijo (cheese bread and cassava flour / tapioca); pamonha (corn and milk paste); esfirra (a variation of Lebanese pastry); kibbeh (from Arabic cuisine); and empada (pastry), little salt pies filled with shrimps or heart of palm. Brazil has a variety of desserts such as brigadeiros (chocolate fudge balls), bolo de rolo (roll cake with goiabada), cocada (a coconut sweet), beijinhos (coconut truffles and clove) and Romeu e Julieta (cheese with goiabada). Peanuts are used to make paçoca, rapadura and pé de moleque.
== Toxicology == Smokeless tobacco is not a "safe" alternative to conventional tobacco; smokeless tobacco products contain nicotine and are therefore highly addictive. They also can cause various harmful effects such as dental disease, oral cancer, oesophagus cancer, and pancreas cancer, coronary heart disease, as well as negative reproductive effects including stillbirth, premature birth and low birth weight. Swallowing gasoline does not generally require special emergency treatment, as long as it goes into the stomach and not the lungs. This does not mean gasoline is safe to drink; it is very dangerous when consumed. Inducing vomiting can make it worse. A chloroform-soaked rag cannot instantly incapacitate a person. It takes at least five minutes of inhaling an item soaked in chloroform to render a person unconscious. Most criminal cases involving chloroform also involve another drug being co-administered, such as alcohol or diazepam, or the victim being found to have been complicit in its administration. The misconception that chloroform can be used as an incapacitating agent has been popularized by crime fiction authors. Although bananas contain naturally occurring radioactive isotopes, particularly potassium-40 (40K), which emit ionizing radiation when undergoing radioactive decay, the levels of such radiation are far too low to induce radiation poisoning, and bananas are not a radiation hazard. It would not be physically possible to eat enough bananas to cause radiation poisoning, as the radiation dose from bananas is non-cumulative.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.